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CD81 T lymphocytes play a key role in controlling viremia during primary human immunodeficiency virus-1 and in
maintaining disease-free infection. It has recently been shown that DNA immunization of rhesus monkeys can elicit strong,
long-lived antigen-specific cytotoxic T lymphocyte (CTL) responses. In previous work, it was shown that macaque CTL
responses to lipopeptide vaccination were directed against a limited number of epitopes. In the present study, we used the
DNA immunization approach to enlarge T cell responses to several epitopes and to multiple isolates. We immunized
macaques with a mixture of six plasmids reflecting the variability of Nef epitopic regions in the simian immunodeficiency virus
(SIV) mac251 primary isolate. The Nef genes from viruses included in the SIVmac251 primary isolate were sequenced and
the six selected sequences were individually subcloned into the pCI vector, under cytomegalovirus enhancer/promoter
control, and injected into macaques. We show that DNA immunization with Nef sequences induced interferon-g (IFN-g)
secreting cell responses directed against several regions of Nef. Reacting T cell lines were expanded in vitro and
multispecific CTL responses mapping the 96–138 Nef region were analyzed. Several peptides recognized by CTL were
identified and studies using peptides reflecting the variability of Nef indicated that all of the Nef variants were recognized in
the 96–138 region. Moreover, CTL responses were directed against an immunodominant epitope located in a functional
region within the Nef protein that is essential for viral replication. This work shows that our approach of DNA immunization
with several sequences induced multispecific T cell responses recognizing variants included in the SIVmac251 primary
isolate. © 2001 Academic Press
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The development of an effective human immunodefi-
ciency virus-1 (HIV-1) vaccine has encountered several
problems. Among them are the antigenic diversity of the
virus and the poor ability of postinfection immune re-
sponses to protect against the development of AIDS.
Indeed, a successful vaccine will need to elicit a broad
spectrum of immune responses that are capable of con-
trolling a diversity of isolates. Evidence is beginning to
accumulate for an important role of CD81 T lymphocytes
both in the containment of early viral replication of HIV
(Borrow et al., 1994, 1997; Klein et al., 1995; Koup et al.,
994; Ogg et al., 1998; Rowland-Jones et al., 1998) and
imian immunodeficiency virus (SIV; Bourgault-Villada et
al., 1997; Jin et al., 1999; Matano et al., 1998; Schmitz et
al., 1999; Venet et al., 1992; Yasutomi et al., 1993) and in
the live attenuated virus- (Connor et al., 1998; Gauduin et
al., 1998) or vaccine- (Gallimore et al., 1995; Robinson et
al., 1999) induced protection of macaques against SIV or
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136simian/human immunodeficiency virus (SHIV) infection.
As live attenuated vaccination is not applicable in hu-
mans, DNA-based immunization appears to be an alter-
native approach to induce CD81 T cell responses. In-
deed, the inoculation of plasmid DNA encoding microbial
proteins allows the endogenous synthesis of the en-
coded protein and its presentation by major histocom-
patibility complex (MHC) class I molecules. DNA immu-
nization elicits long-term immunity, which may be essen-
tial in an AIDS vaccine (Donnelly et al., 1997). It has been
shown that antigen-expressing plasmids can raise the
protective immunity against infectious diseases such as
influenza (Thomson et al., 1998; Ulmer et al., 1998), lym-
phocytic choriomeningitis virus (Martins et al., 1995;
okoyama et al., 1995), and malaria (Becker et al., 1998;
chneider et al., 1998; Sedegah et al., 1998). Recently, the
otential of this vaccine technology was demonstrated
y the induction of multiepitopic CD81 CTL in malaria-
naive humans by a malaria DNA vaccine, which included
cytotoxic T lymphocyte (CTL) that were restricted by
multiple human lymphocyte antigen (HLA) class I alleles
in the same individual (Wang et al., 1998). Few studies
have been done on DNA-induced immunity to HIV in
humans. The presence of CTL responses in HIV-infected
individuals after vaccination with plasmids encoding HIV
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137SIV NEF DNA VACCINE ELICITED T CELL IMMUNITYproteins has been reported (Calarota et al., 1998;
MacGregor et al., 1998). However, the role of the plas-
mids versus the virus in the CTL induction was not clear.
In the macaque model, it has been shown that DNA
vaccines elicit antibodies, as well as CD41 T and CD81
T cell responses including CTL (Lekutis et al., 1997; Lu et
l., 1996; Yasutomi et al., 1996). Persistent CTL and tran-
ient antibody responses have been observed (Lu et al.,
996). Indeed, containment of highly attenuated HIV-1,
onpathogenic SHIV (Boyer et al., 1997; Letvin et al.,
997), and even virulent SHIV infection challenges (Rob-
nson et al., 1999) can be achieved under particular DNA
mmunization protocols. In a previous vaccination trial of
acaques with lipopeptides, we induced CD81 CTL re-
sponses directed against a single SIV Nef epitope and
showed that the induction of such monoepitopic re-
sponses did not protect macaques from infection (Mort-
ara et al., 1998). In addition, a recent work clearly dem-
onstrated an inverse correlation between the number of
epitopes recognized by CTL and the progression to dis-
ease in SIV-infected monkeys (Evans et al., 1999).
Here, we have chosen to immunize macaques with
SIV Nef-encoding plasmids. Nef is one of the first pro-
teins produced following infection and is highly immuno-
genic in most SIV-infected macaques (Bourgault et al.,
1992, 1993; Venet et al., 1992) as well as in HIV-infected
individuals (Culmann-Penciolelli et al., 1994; Haas et al.,
1997; Hadida et al., 1992; Koenig et al., 1990). In the
present work, the DNA vaccine approach was used to
induce a broad T cell immune response. With this aim,
macaques were injected with plasmids containing six
different Nef sequences. The sequences were selected
FIG. 1. Nef amino acid sequences from SIVmac251 primary isolate. S
CLUSTAL program. Known T cell epitopic regions considered for the
underlined.from the uncloned SIVmac251 primary isolate as repre-
sentative of Nef variability in the known epitopic regions.This work shows that DNA immunization with several
sequences elicits multispecific T cell responses that
recognize several epitopes expressed in the different
Nef immunogens.
RESULTS
Nef sequences from SIVmac251 primary isolate
To evaluate the variability inside the SIVmac251 pri-
mary isolate, we sequenced the Nef genes from viruses
included in this isolate. Figure 1 displays the nine rep-
resentative amino acid Nef sequences obtained from the
SIVmac251 isolate. Sequences were aligned using the
CLUSTAL program (Higgins and Sharp, 1989) and intra-
variability was estimated according to Kimura’s two-pa-
rameter method (Kimura, 1980). The intravariability of Nef
was 3.56% for nucleotide sequences and 2.18% for amino
acid sequences. For Gag from the same isolate, the
intravariability was 1.02% for nucleotide sequences and
0.87% for amino acid sequences. These sequences were
aligned to the BK28 molecular clone (GenBank Acces-
sion No. M19499). We focused on the known T cell
epitope-containing regions, 101–147, 155–178, and 201–
247 (Bourgault et al., 1992; Mortara et al., 1999) to select
six sequences representative of Nef variability in the
SIVmac251 isolate. The selected nucleotide sequences
(BK28, S4, S5, S8, S9, and S12), each encoding for a
complete Nef gene, were individually subcloned into the
pCI vector, under the control of the cytomegalovirus
(CMV) enhancer/promoter. Transient transfections of
COS-7 cells with the resulting plasmids were carried out
to verify the ability of the vector to direct protein produc-
es were aligned to the SIVmac251 BK28 molecular clone by using the
on are indicated. Nef sequences selected for DNA immunization areequenction before in vivo injection (not shown). To induce mul-
tispecific immune responses, macaques were immu-
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138 COUILLIN ET AL.nized with the mixture of six plasmids on days 0, 20, and
40 by subcutaneous injections and received two addi-
tional intramuscular injections at months 5 and 6. Control
macaques were immunized with an equal amount of
“empty” pCI vector.
IFN-g responses induced by DNA vaccination
To study the in vivo induction of specific T cell im-
mune responses, sensitive enzyme-linked immunospot
(ELISPOT) assays were used to assess interferon-g
(IFN-g) production by peripheral blood mononuclear
ells (PBMC) stimulated with Nef peptides (Fig. 2). Pep-
ides, corresponding to the Nef BK28 sequence, were
ixed to make seven pools (pool A to G) of six or seven
eptides, as indicated under the Materials and Methods
ection, and used to stimulate freshly isolated PBMC for
to 12 days before performing ELISPOT assays with the
ame pools. In these experiments, PBMC were collected
to 12 months after the last DNA injection. Significant
FIG. 2. Secretion of IFN-g after stimulation of PBMC with different pools
of Nef peptides. Pool-specific IFN-g responses are shown for immunized
macaques 90220 (A), 92057 (B), 91043 (C), 92137 (D), and for the control
macaque 92001 (E). ELISPOT assay was performed in the presence (gray
bars) or absence (dark bars) of the corresponding peptide pool after 6
days of in vitro culture with the relevant peptide pool.ata were obtained after this 6–12 day in vitro amplifica-
tion, which allowed both an increase of specific signaland a decrease in background. IFN-g secretion re-
sponses were detected for all of the immunized ma-
caques. The highest responses were obtained for ma-
caque 90220 in the presence of pool D or G (Fig. 2A) and
macaque 92057 in the presence of pool D, F, or G (Fig.
2B). Weaker responses were observed in both of the
other immunized macaques: in the presence of pool E for
macaque 91043 (Fig. 2C) and pool D or F for macaque
92137 (Fig. 2D). No response was found with the control
macaque 92001 (Fig. 2E). For three out of the four immu-
nized macaques, anti-Nef IFN-g secretion was detected
in response to pool D, corresponding to the 96–138
region.
To assess the in vivo priming of macaques by DNA
immunization and to discard the possibility of an in vitro
nduction of IFN-g secreting cells during culture, we
investigated the IFN-g secretion response from cells
sampled before in vivo immunization compared with
those sampled 6 months after the last immunization. In
both cases PBMC were viably frozen at the time of
sampling. We focused on the 96–138 region that was the
most frequently recognized. As shown in Fig. 3 for ma-
caque 92057, no IFN-g secreting cells were detected in
the presence of pool D from the preimmunization sample
in contrast with the postimmunization sample. No re-
sponse was obtained in the presence of medium alone.
The lower number of IFN-g secreting cells detected in
this experiment when compared to the previous one was
due to the freezing and thawing of PBMC before the
assay.
To determine the PBMC subpopulations involved in
IFN-g secretion responses, CD4 and CD8 depletion ex-
periments were carried out after 12 days of in vitro
stimulation with pool D. Undepleted and depleted cells
were tested for IFN-g secretion in the presence of pool
D. As shown in Fig. 4 for macaques 90220 and 92057, the
depletion of CD81 T cells dramatically decreased the
number of IFN-g spot forming cells (SFC), indicating the
major involvement of these cells in the IFN-g response.
The same conclusion was made from tests using posi-
tive fractions (not shown). Nevertheless, CD41 T cell
mediated IFN-g secretion was also observed with ma-
FIG. 3. Comparison of IFN-g secretions from preimmunization and
postimmunization samples from macaque 92057. PBMC from macaque
92057 were frozen at the time of blood sample processing then thawed
and cultured in vitro for 12 days with peptide pool D. An ELISPOT assay
was then performed in the presence (gray bars) or absence (dark bars)
of pool D.
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139SIV NEF DNA VACCINE ELICITED T CELL IMMUNITYcaque 90220 and was, in this case, mainly directed
against peptide 116–130 (not shown).
CTL activities
Region Nef 96–138 (pool D), in which several T cell
epitopes have already been described, was the most
FIG. 4. Involvement of CD41 and CD81 T cells in specific IFN-g
secretion. Undepleted and depleted cells (CD42 and CD82) from ma-
aques 90220 (A) and 92057 (B) were tested for IFN-g secretion in the
presence (gray bars) or in the absence (dark bars) of pool D.
FIG. 5. Cytotoxic activities toward peptides from region 96–138. Cyto
A and C) and 92057 (B and D) for the lysis of autologous B-LCL sen
ecombinant vaccinia virus (C and D). Vac Env was used as negative control
percentage of specific lysis. Cytotoxic assays were performed 18 days postsfrequently recognized region by IFN-g secreting cells.
Therefore, we focused on this region to study the spec-
ificities of CTL induced by DNA immunization. Antipool D
cell lines from 90220 and 92057’s PBMC were expanded
in vitro to study their cytotoxic activities vis-a`-vis pep-
ides from the 96–138 region BK28 sequence (Fig. 5A and
B). As shown in Fig. 5A, the CTL response was directed
gainst peptide 108–123 only for macaque 90220. For
acaque 92057, pool D-specific CTL were able to rec-
gnize three out of the six overlapping peptides included
n this pool: peptides 108–123, 120–135, and 125–138
Fig. 5B), indicating that the response was multispecific
ithin the region 96–138. CTL recognizing synthetic pep-
ides were also able to lyse Vac–Nef-infected autologous
arget cells indicating that they also recognized the nat-
rally processed peptides (Figs. 5C and 5D).
To assess the CTL response against the different
equences injected into macaques, the antipool D cell
ines were tested for their ability to cross-recognize pep-
ides corresponding to Nef variants (Fig. 6). For macaque
0220, both 108–123 peptides from sequences BK28
LRAMTYKLAIDMSHFI) and S4 (LRTMSYKLAIDMSHFI)
ere recognized (Fig. 6A). For macaque 92057, similar
esults were obtained in response to the 108–123 se-
uences (Fig. 6B) and to the 125–138 sequences (Fig.
C). These results indicated that all Nef SIV sequences
ncluded in the DNA vaccine were recognized by CTL
rom both macaques.
tivities were assayed with antipool D cell lines from macaques 90220
with the indicated peptides (A and B) or infected with the indicatedtoxic ac
sitized. Mean values for 51Cr release from target cells are expressed as the
timulation.
C). Ta
tch the
140 COUILLIN ET AL.Unpublished data suggested that the BK28 sequence
in region 108–123 was a poor CTL inducer, whereas
macaques infected with SIVmac251 isolate generated
CTL recognizing the peptide 108–123 as well as the
shorter peptide 112–119. We therefore induced CTL from
macaque 92057’s PBMC by in vitro stimulation with pep-
tide 108–123 from either BK28 (Fig. 7A) or S4 variant (Fig.
7B) sequence. Both antipeptide cell lines were tested for
their ability to recognize peptide 112–119 from BK28
(TYKLAIDM) and peptide 112–119(S4) (SYKLAIDM) from
variant sequence. Figure 7 shows that in both cases,
higher levels of specific lysis were obtained with peptide
112–119(S4) than with peptide 112–119. Similar results
were obtained with PBMC from macaque 90220 (not
shown).
DISCUSSION
In the present work, we have shown that DNA immu-
1
FIG. 6. Specific cytotoxic activities against variable sequences in the
with antipool D cell lines from macaques 90220 (A) and 92057 (B and
Peptide sequences are shown and amino acid positions which mismanization allows the induction of Nef SIV-specific CD8 T
cells. Specific secretion of IFN-g was obtained for thefour immunized macaques. These responses were di-
rected against four regions of the Nef protein (96–138,
133–176, 164–210, and 201–247). DNA immunization with
the whole gene enabled specific responses to be ob-
tained in different MHC contexts, although the strength
of the response was certainly dependent on the MHC
haplotype of the macaque. Two macaques developed
weak IFN-g responses against one or two of the regions,
whereas higher responders recognized two or three re-
gions of the Nef protein. These results confirm that DNA
immunization with a whole gene can induce multi-
epitopic responses. Both high responders recognized
the same two regions of the Nef protein (96–138 and
201–247). Region 96–138 (corresponding to peptide pool
D) appears to be immunodominant since it was recog-
nized by three out of four immunized macaques. The
analysis of the response against this region showed that
CD81 T cells were predominantly involved in anti-Nef
1
–138 region. Cytotoxic assays were performed 18 days poststimulation
rget cells were autologous B-LCL incubated with indicated peptides.
BK28 sequence are underlined.Nef 96IFN-g secreting cell responses. Nevertheless, CD4 T
cells could also play an important role in the induction of
c
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served in humans (Livingston et al., 1997; Vitiello et al.,
1995) and in macaques vaccinated with lipopeptides
(Mortara et al., 1999). Anti-Nef IFN-g secreting cell re-
sponses were associated with CTL responses. Within
the 96–138 region, the response was multispecific for
macaque 92057 since at least three regions (108–123,
120–135, and 125–138) were recognized. Elicitation by
immunization of the CTL response against many
epitopes is of great importance in preventing the emer-
gence of escape mutant virus during primary infection
(Evans et al., 1999).
We showed here that DNA immunization with several
sequences of Nef genes elicited CTL responses. Inter-
estingly, these CTL which were screened in vitro for their
ability to recognize peptides from the BK28 96–138 re-
gion were also able to recognize epitopic peptides from
the variant sequences. In the 112–119 region, although
both peptides 112–119/112T (TYKLAIDM) and 112–119/
112S (SYKLAIDM) were recognized by the induced CTL,
our results showed that the latter was a better antigen.
Interestingly, this region has been described as being
epitopic for CTL from SIVmac251-infected macaques
(Bourgault et al., 1992), whereas macaques immunized
with lipopeptides from the BK28 sequence failed to re-
FIG. 7. Recognition of peptides 112–119 (TYKLAIDM) and 112–119(S4)
(SYKLAIDM). Antipeptide Nef 108–123 cell line (A) and antipeptide Nef
108–123 (S4) cell line (B) from macaque 92057 were used in cytotoxic
assays for the lysis of autologous B-LCL targets sensitized with peptide
112–119 (gray bars) or 112–119(S4) (black bars) at the indicated con-
centration. Cytotoxic assays were performed 12 days poststimulation at
an effector to target ratio of 30/1.spond to this region (Mortara et al., 1999). Altogether
these observations suggest that the 112–119/112T se-quence (corresponding to BK28) would be unable to
induce CTL responses in vivo in contrast with the 112–
119/112S sequence (predominant in SIVmac251 isolate).
Immunizations with the single BK28 sequence would not
allow the induction of CTL responses specific for the
112–119 epitope albeit the corresponding peptide can be
presented to CTL. The lack of immunogenicity of the
112T sequence (BK28) would be overcome by cross-
reacting CTL induced by the 112S sequences.
CTL responses recognizing these 112–119 peptides
might be of particular importance in vaccine develop-
ment due to their location in a functional region of the
Nef protein. Indeed, the 112–119/112S sequence
(SYKLAIDM) shares five residues with the region 106–116
(VPLRTMSYKLA), which has been described as a con-
served potential protein kinase C phosphorylation site
(Huang et al., 1995; Shugars et al., 1993). Moreover,
recent data strongly suggested that this region together
with an acidic region (87–97) within Nef are important for
efficient viral replication and pathogenicity of SIV and are
involved in down-regulating the cell surface expression
of CD4 and MHC class I molecules (Carl et al., 1999).
Vaccine-induced immune responses toward such an
epitope might prevent or delay the emergence of CTL
escape variants as recently proposed for a highly con-
served CTL epitope from the HIV-1 p24 protein (Harrer et
al., 1996; Wagner et al., 1999).
Our results point out the Nef variability in the virus
populations in infected individuals and the need to con-
sider this variability when developing a vaccine. This
development will be facilitated by a DNA immunization
approach that uses a mixture of several entire se-
quences with the consequent induction of broad immune
responses.
MATERIALS AND METHODS
Reverse transcription PCR
Viral isolate RNA was extracted from 400 ml of viral
stock with 300 ml of phenol acid (Appligene Oncor,
Illkirch, France) and 300 ml of extraction buffer (7 M urea,
0.35 M NaCl, 10 mM Tris–HCl pH 7.5, 10 mM EDTA, 1%
sodium dodecyl sulfate). After vortexing and centrifuga-
tion, the supernatant was extracted twice with phenol,
twice with chloroform and ethanol precipitated with 2 mg
of tRNA. After centrifugation, the RNA pellet was washed
with 70% ethanol, dried, and resuspended in 50 ml of
sterile water. Five microliters was subjected to reverse
transcription for 1 h at 37°C with a 25 ml reaction mixture
ontaining 50 mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM
gCl2, 8 mM dithiothreitol, 400 mM each dNTP, 50 pmol
of primer Nef2 (59-AGAACCTCCCAGGGCTCAATCT-39),
30 U of RNasin (Promega, Madison, WI), and 200 U of
Moloney murine leukaemia virus reverse transcriptase
(Gibco BRL Life Technologies, Gaithersburg, MD). Five
microliters of the cDNA mixture was amplified under the
142 COUILLIN ET AL.following conditions: PCR were performed in 100 ml re-
action mixtures containing 200 mM each dNTP (Pharma-
cia, Uppsala, Sweden), 10 mM Tris–HCl (pH 8.3), 50 mM
KCl, 1.5 mM MgCl2, 2.5 U of Taq polymerase (Gibco BRL
Life Technologies), and 20 pmol of primer VJ11 (59-AT-
GGGTGGAGCTATTTCCATG-39) and VJ12 (59-TTAGCCT-
TCTTCTAACCTC-39). The reactions were carried out with
a DNA Thermocycler 9600 (Perkin–Elmer, Branchburg,
NJ) for 40 cycles. The first step was 1 min at 96°C; the
following steps were 30 s at 95°C, 30 s at 55°C and 1
min at 72°C, with a final incubation at 72°C for 5 min.
Cloning and sequencing
After purification on a Qiaquick column (Qiagen,
Courtaboeuf Les Ullis, France), 50 ng of the PCR product
was ligated overnight at 15°C with 50 ng of pTAg vector
(R&D Systems Europe, Abingdon, UK) in a 10-ml reaction
mixture containing 50 mM Tris–HCl (pH 7.6), 10 mM
MgCl2, 1 mM ATP, 1 mM dithiothreitol, 5% polyethylene
glycol 8000, and 1 U of T4 DNA ligase (Gibco BRL Life
Technologies). Escherichia coli TG1 were transformed
with the ligation product (0.1 ml) and the few white colo-
nies obtained on Luria-Bertani plates with ampicillin
were selected. DNA was extracted with the Easy Prep
Plasmid Prep Kit (Pharmacia) and 500 ng was se-
quenced using dye terminator chemistry on a 373A se-
quencer (ABI/Perkin–Elmer, Norwalk, CT). All the se-
quences obtained were aligned with the SeqEd program
(ABI/Applied BioSystems). XhoI/MluI or MluI/NotI frag-
ments were subcloned from pTAg–Nef plasmids into the
polylinker of plasmid pCI (Promega) to make the pCI-Nef
plasmids. The XhoI/MluI or MluI/NotI enzyme (New En-
gland Biolabs Ltd., Hitchin, UK) combinations were used
depending on the orientation of the Nef gene in pTAg as
determined by sequencing. After digestion, the DNA
were isolated on a 1% agarose gel and extracted using a
QiaEx II kit (Qiagen). Ninety nanograms of each Nef
fragment were ligated overnight at 16°C with 20 ng of
pCI vector. Insert orientations were confirmed by PCR
and restriction enzyme analysis. Plasmid DNA was pu-
rified on Qiagen columns and tested for expression in
COS-7 cells. Milligram amounts of each plasmid were
produced by Interchim (Montluc¸on, France) under endo-
toxin-free conditions.
Animals and immunization protocol
Four male rhesus macaques (Macaca mulatta) (90220,
91043, 92057, and 92137) received intradermic injections
of 900 mg of a mixture of the six pCI–Nef plasmids (150
mg each) in 150 ml of phosphate-buffered saline (PBS) (3
shots of 50 ml in the top back skin) at weeks 0, 3 and 6.
At weeks 22 and 26 the macaques received 2 mg of the
same mixture intramuscularly in two injections of 500 ml
each in the inner face of each thigh. Macaque 92001received the control empty pCI vector under the same
conditions.
Synthetic peptides
Nef peptides were synthesized by Neosystem (Stras-
bourg, France). Fourteen- to 17-amino acid overlapping
peptides (mostly 15-mer) spanning the entire sequence
of NefBK28 were mixed to make seven pools (pools A to
G) of six or seven peptides. The pools contained the
following peptides: pool A (1–15, 6–20, 11–25, 16–30,
21–35, 26–40), pool B (31–45, 36–50, 41–54, 46–50, 51–65,
56–70), pool C (61–75, 66–80, 74–88, 80–93, 84–98,
91–105), pool D (96–110, 101–115, 108–123, 116–130, 120–
135, 125–138), pool E (133–147, 140–155, 146–160,
150–165, 155–169, 160–176), pool F (164–178, 170–185,
176–190, 184–197, 191–205, 195–210), and pool G (201–215,
205–220, 211–225, 215–230, 221–235, 225–240, 232–247).
Processing of blood samples
PBMC were recovered after Ficoll–Hypaque (Pharma-
cia) density gradients and were used immediately or
viably frozen. Antipeptide CTL cell lines were obtained by
culturing PBMC (2 3 106 cells/ml) in 24-well microtiter
plates (Costar, Cambridge, MA) in Roswell Park Memo-
rial Institute (RPMI) 1640 medium with 100 U/ml penicil-
lin, 100 mg/ml streptomycin, 2 mM L-glutamine, 1% non-
essential amino acids, 1 mM sodium pyruvate, 10 mM
HEPES buffer, 2 3 1025 M 2-mercaptoethanol, and 5%
heat-inactivated autologous plasma (complete medium)
with or without the different pools of Nef peptides at 10
mg/ml for each peptide. Then, IL-2 (Boehringer Mann-
heim, Meylan, France) was added to each well (20 UI/ml)
after one day of incubation.
Separation of lymphocyte subsets
Magnetic beads coated with goat anti-mouse antibod-
ies (Bio Advance, Emerainville, France) were incubated
overnight at 4°C with OKT4 (Ortho Diagnostic Systems,
Raritan, NJ) and MT310 (Dako, Glostrup, Denmark) anti-
CD4 monoclonal antibodies (mAb) or with anti-CD8
Leu-2a (Becton Dickinson, San Jose, CA) and DK25
(Dako) anti-CD8 mAb. After washes, depletions from ef-
fector cells were performed by incubating cells with
antibody complexes for 2 h at 4°C. Negative and positive
depletion fractions were collected according to the man-
ufacturer’s instructions. The purity of the negative sub-
populations was monitored by immunolabeling with anti-
CD4 (Cymbus Biotechnology, Hants, UK) and anti-CD8
antibodies (Serotec, Oxford, UK). These procedures re-
sulted in less than 9 and 2%, respectively, of CD4 and
CD8 contaminating cells as assessed by flow cytometry.
ELISPOT assay for single-cell IFN-g releaseEffector cells were washed twice after 6 or 12 days of
culture and resuspended in complete medium. Ninety-
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143SIV NEF DNA VACCINE ELICITED T CELL IMMUNITYsix-well nitrocellulose plates (Multi-Screen HA, Millipore,
Bedford, MA) were coated overnight at 4°C with 50 ml of
aptured mouse anti-human IFN-g mAb (Genzyme, Rus-
selheim, Germany) at 8 mg/ml diluted in 0.1 M carbonate
buffer, pH 9.5. Plates were washed six times with RPMI
and blocked with 200 ml of complete medium for 2 h at
7°C. 105 or 2 3 105 effector cells/well in 100 ml were
incubated in duplicate with the different pools of Nef
peptides (10 mg/ml of each peptides) for 24 h. Plates
were then washed six times with PBS 0.05% Tween 20
(PBS-T) before adding 100 ml of polyclonal rabbit anti-
human IFN-g antibody (Genzyme) at 1:250 dilution in
PBS-T 1% BSA (PBS-T-BSA). After an overnight incubation
at 4°C, the plates were washed six times and 100 ml of
olyclonal biotin-conjugated goat anti-rabbit IgG anti-
ody (Boehringer Mannheim) at 1:500 dilution was
dded to the wells and the plates were incubated for 2 h
t 37°C. The plates were washed six times and 100 ml of
alkaline phosphatase-labeled extravidin (Sigma, l’Isles
d’Abbeau, France) at 1:5000 dilution was added to the
wells for 1 h at 37°C. The plates were then washed again
ix times and 100 ml of chromogenic alkaline phospha-
tase conjugate substrate (BioRad, Hercule, CA) diluted
1:25 with deionized water was added. After 30 min of
incubation, the substrate solution was discarded and
plates were washed under running water and air-dried.
Spots were visualized using a stereomicroscope (Leica
MZ6, Heerbrugg, Switzerland) with a magnification of
340. Only spots with fuzzy borders were scored as
IFN-g-SFC and results were expressed as IFN-g SFC per
106 cells.
n vitro transformation of B cell lines
B-lymphoblastoid cell lines (B-LCL) were generated by
ncubating serial dilutions of PBMC with supernatant
rom the S 594 cell line. This line (kindly provided by N.
etvin) produces the immortalizing baboon herpes virus
herpes papio virus). B-LCL were then cultured in me-
ium supplemented with 10% FCS.
ecombinant vaccinia viruses
The sequences encoding the Nef or Env proteins from
IV BK28 were inserted into vaccinia virus (Copenhagen
train). All the constructions were prepared by Trans-
ene (Strasbourg, France).
hromium release assay
Effector cells were generated from T cell lines treated
s indicated above and expanded in vitro by addition of
IL-2 (20 IU/ml) every 3 days for 18 days. Peptide-sensi-
tized target cells were generated by incubating B-LCL
(0.5 3 106/ml) overnight with 1025 M peptides, or the
indicated concentration, at 37°C in a humidified 5% CO2
atmosphere. To obtain target cells expressing SIV Nef or
Env, B-LCL were incubated at a concentration of 106
Ccells/ml with the relevant recombinant vaccinia virus (20
PFU/cell) for 18 h under the same conditions. The B-LCL
were then washed, labeled with 100 mCi of Na2
51CrO4
(NEN Life Science Products, Courtaboeuf Les Ullis,
France) for 1 h, washed twice, and used as target cells.
The assay was performed in V-bottom 96-well microtiter
plates. The cytolytic activity was measured by mixing 5 3
103 51Cr-labeled target cells with effector cells at various
effector cell/target cell (E/T) ratios in a final volume of
200 ml/well. Duplicate wells were seeded for each E/T
ratio. Plates were incubated for 4 h at 37°C; 100 ml of
supernatant was then removed from each well and an-
alyzed with a gamma counter. Spontaneous release was
determined by incubating target cells with medium
alone; it never exceeded 20% of the total 51Cr incorpo-
rated. Results are expressed as the percentage of spe-
cific lysis 5 100 3 (experimental counts per minute 2
pontaneous counts per minute)/(maximum counts per
inute 2 spontaneous counts per minute). The within-
ample variation never exceeded 5% of the absolute
ounts per minute.
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